Although, plasma P‐tau may prove to have significant utility in detection of concomitant AD in patients with DLB or PDD, further studies are needed to substantiate its performance and validate its use prior to implementation in a clinical setting or in clinical trials. Here, MAPT is linked to Alzheimer disease.